Publications by authors named "Avelino Kuran"
Article Synopsis
- Remdesivir is the only antiviral drug approved for hospitalized COVID-19 patients needing supplemental oxygen, but studies on its effect on mortality have shown mixed results.
- In this study, researchers compared hospitalized COVID-19 patients treated with remdesivir to controls, using a matching method to balance the groups, focusing on in-hospital mortality and length of stay.
- The overall results indicated no significant difference in mortality between the two groups, but subgroup analyses revealed lower mortality in women and in patients treated within 7 days of symptom onset, although patients treated with remdesivir had a longer hospital stay.
Background: Tocilizumab and baricitinib are recommended treatment options for hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and safety in a head-to-head comparison is scarce.
Methods: Hospitalized COVID-19 patients requiring oxygen were treated with tocilizumab or baricitinib additionally to dexamethasone.
Purpose: Cancer is becoming increasingly prevalent among the group of treatable diseases in African countries. There is a shortage of clinicians and pathologists available for cancer diagnosis and treatment. These limited resources must be efficiently used to maximize the number of patients treated.
View Article and Find Full Text PDF